This article is more than 5 years old. Information may no longer be current.
New accommodating IOL provides excellent visual acuity, contrast sensitivity
NEW ORLEANS — A slightly modified fourth-generation accommodating IOL currently in clinical trials gave patients excellent intermediate and near vision, as well as good contrast sensitivity, according to a physician here.
|
During the annual American Academy of Ophthalmology meeting, John A. Hovanesian, MD, presented 4 to 6 months results from 60 patients who received the crystalens HD-100 (eyeonics) in one eye. They were treated in the ongoing clinical trial for the Food and Drug Administration's approval of this new lens. He said eyeonics is hoping to launch the lens a year from now, pending approval.
"The new generation seems to provide very acceptable uncorrected vision at all distances, and is clearly an improvement upon the results of the currently approved IOLs, without degrading contrast sensitivity," Dr. Hovanesian said at the free paper session.
In his presentation, Dr. Hovanesian said that for uncorrected monocular intermediate distance vision, 80% of patients with the crystalens HD saw 20/20 or better; 93% saw 20/25; 96.6% saw 20/32 or better; and 100% saw 20/40 or better. For uncorrected monocular near visual acuity, 55% of patients saw J1 or better; 80% saw J2 or better; and 100% saw J3 or better. Contrast sensitivity also remained equal to or better than the FDA-approved crystalens AT-45.
Dr. Hovanesian said his data set was within ±0.5 D of the intended target.
Dr. Hovanesian is one of four investigators who are required to implant the lens in a total of 125 patients for the FDA study. He said the lens is a "proprietary optic design modification," of the crystalens Five-O platform. While the exact modifications could not yet be divulged because the lens is still in clinical trials, it is being designed to improve near vision, Dr. Hovanesian said.